Lodelcizumab, a recently developed monoclonal antigen, represents a exciting solution in the fight against severe migraines. Unlike many current therapies that address pain immediately, lodelcizumab selectively blocks CGRP, a key protein associated in migraine onset. This unique way of function may offer a meaningful advantage for patients who h… Read More

A Deep Dive into the Antibody SGN-70 Vorsetuzumab represents a exciting approach in cancer, specifically targeting the CD22 antigen expressed on hematologic malignancies. Developed by the researchers, the agent functions as an antibody-dependent cellular cytotoxicity (ADCC) inducer, promoting natural eli… Read More